Clinical OMICS

JAN-FEB 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1071882

Contents of this Issue

Navigation

Page 32 of 51

www.clinicalomics.com January/February 2019 Clinical OMICs 31 Liachko said that sometimes, "you need more than a sequence. Sometimes you need to know the location of a piece of DNA." Proximity ligation tools such as Hi-C allow the capture of sequences that are physically close to each other in the nucleus, enabling haplotype phasing—or deter- minations of which two sequences are on the same chromo- some, and of which mutations are on the same haplotype. By allowing genomic structural and phase information to be obtained in just a day from a library preparation kit, the Phase Genomics technology gives genomic science a power it previously lacked and sorely needed. Identifying 'Fevers of Known Origins' Although next-generation sequencing (NGS) may be best known for its use in oncology, the researchers at Karius are using it to transform infectious disease diagnosis through the detection of cell-free DNA (cfDNA). The test that Karius has developed is currently able to detect more than 1,000 disease-causing pathogens, including protozoa, bacteria, fungi, nematodes, and viruses, by identifying microbial cfDNA in patients' plasma. Mickey Kertesz, Ph.D., cofounded Karius in 2014 to bring the pathogen detection technology he and col- leagues developed at Stan- ford University into the hospital. One of Kertesz' Stanford colleagues, David Hong, M.D., is now Karius' vice president of medical affairs and clinical devel- opment. Hong joined Kar- ius four years ago because of the problems that he was facing on the pediatric infectious disease ward— problems common to hos- pitals everywhere. In a hospital, every patient is at risk for infection, and to Hong's frustration, the technology available for detecting infections is decades old with many limitations. seksan Mongkhonkhamsao / Getty Images (continued on next page) Mickey Kertesz, Ph.D. Founder, Karius Researchers at Karius are leveraging NGS for infectious disease diagnosis through the detection of cell-free DNA (cfDNA).

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2019